201 related articles for article (PubMed ID: 22171202)
21. Medication-associated somnambulism.
Lange CL
J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):211-2. PubMed ID: 15725964
[No Abstract] [Full Text] [Related]
22. Zolpidem and driving impairment--identifying persons at risk.
Farkas RH; Unger EF; Temple R
N Engl J Med; 2013 Aug; 369(8):689-91. PubMed ID: 23923991
[No Abstract] [Full Text] [Related]
23. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia.
Erman MK; Zammit G; Rubens R; Schaefer K; Wessel T; Amato D; Caron J; Walsh JK
J Clin Sleep Med; 2008 Jun; 4(3):229-34. PubMed ID: 18595435
[TBL] [Abstract][Full Text] [Related]
24. Spontaneous Adverse Event Reports Associated with Zolpidem in the United States 2003-2012.
Wong CK; Marshall NS; Grunstein RR; Ho SS; Fois RA; Hibbs DE; Hanrahan JR; Saini B
J Clin Sleep Med; 2017 Feb; 13(2):223-234. PubMed ID: 27784418
[TBL] [Abstract][Full Text] [Related]
25. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
[TBL] [Abstract][Full Text] [Related]
27. Somnambulism due to probable interaction of valproic acid and zolpidem.
Sattar SP; Ramaswamy S; Bhatia SC; Petty F
Ann Pharmacother; 2003 Oct; 37(10):1429-33. PubMed ID: 14519043
[TBL] [Abstract][Full Text] [Related]
28. Zolpidem-associated parasomnia with serious self-injury: a shot in the dark.
Gibson CE; Caplan JP
Psychosomatics; 2011; 52(1):88-91. PubMed ID: 21300202
[No Abstract] [Full Text] [Related]
29. A polysomnographically documented case of adult somnambulism with long-distance automobile driving and frequent nocturnal violence: parasomnia with continuing danger as a noninsane automatism?
Schenck CH; Mahowald MW
Sleep; 1995 Nov; 18(9):765-72. PubMed ID: 8638069
[TBL] [Abstract][Full Text] [Related]
30. Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans.
Morgan PT; Kehne JH; Sprenger KJ; Malison RT
J Sleep Res; 2010 Mar; 19(1 Pt 2):157-64. PubMed ID: 19682231
[TBL] [Abstract][Full Text] [Related]
31. FDA requires lower dosing of zolpidem.
Med Lett Drugs Ther; 2013 Jan; 55(1408):5. PubMed ID: 23348358
[No Abstract] [Full Text] [Related]
32. Spontaneous adverse event reports associated with zolpidem in Australia 2001-2008.
Ben-Hamou M; Marshall NS; Grunstein RR; Saini B; Fois RA
J Sleep Res; 2011 Dec; 20(4):559-68. PubMed ID: 21481053
[TBL] [Abstract][Full Text] [Related]
33. Zolpidem for insomnia.
Greenblatt DJ; Roth T
Expert Opin Pharmacother; 2012 Apr; 13(6):879-93. PubMed ID: 22424586
[TBL] [Abstract][Full Text] [Related]
34. Hypnosedative use and predictors of successful withdrawal in new patients attending a falls clinic: a retrospective, cohort study.
Joester J; Vogler CM; Chang K; Hilmer SN
Drugs Aging; 2010 Nov; 27(11):915-24. PubMed ID: 20964465
[TBL] [Abstract][Full Text] [Related]
35. Clinical correlates of zolpidem-associated complex sleep-related behaviors: age effect.
Chen CS; Huang MF; Hwang TJ; Chen ST; Ko CH; Yen CN; Chen TT; Su PW; Yeh YC; Lin JJ; Yen CF
J Clin Psychiatry; 2014 Nov; 75(11):e1314-8. PubMed ID: 25470097
[TBL] [Abstract][Full Text] [Related]
36. Putting "sleepdriving" and new safety warning in perspective.
Johns Hopkins Med Lett Health After 50; 2007 Aug; 19(6):1-2. PubMed ID: 17712908
[No Abstract] [Full Text] [Related]
37. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases.
Hajak G; Bandelow B
Int Clin Psychopharmacol; 1998 Jul; 13(4):157-67. PubMed ID: 9727726
[TBL] [Abstract][Full Text] [Related]
38. Sleepwalking associated with zolpidem.
Mendelson WB
J Clin Psychopharmacol; 1994 Apr; 14(2):150. PubMed ID: 8195460
[No Abstract] [Full Text] [Related]
39. Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia.
Zammit G; Wang-Weigand S; Rosenthal M; Peng X
J Clin Sleep Med; 2009 Feb; 5(1):34-40. PubMed ID: 19317379
[TBL] [Abstract][Full Text] [Related]
40. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia.
Perlis ML; McCall WV; Krystal AD; Walsh JK
J Clin Psychiatry; 2004 Aug; 65(8):1128-37. PubMed ID: 15323600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
